Shares of Hemispherx Biopharma (NYSEAMERICAN:HEB) soared Tuesday after the company announced “significant progress” in the study of its flagship drug Ampligen in treating ovarian cancer.
Hemispherx’s stock recently traded at $0.24 a share, up 41% on heavy volume.
READ: Hemispherx Biopharma kicks off Phase 1 trial to treat advanced breast cancer with key drug Ampligen
The study currently is being conducted at the University of Pittsburgh Medical Center (UPMC), the company said in statement.
The Orlando, Florida-based company also noted it is now accruing patients for a second ovarian cancer clinical trial at UMPC to evaluate Ampligen in combination with drug Pembrolizumab.
Hemispherx also is studying separately whether Ampligen is effective in treating breast cancer in combination with Merck’s (NYSE:MRK) cancer drug Keytruda.
Contact the author: [email protected]
Follow him on Twitter @patrickmgraham